Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc. (IDYA)
Filing Type: Form 8-K (Current Report)
Date of Report: October 17, 2025
Reporting Period: Events reported on October 17, 2025, and October 20, 2025.
Business Overview: The Company is a biopharmaceutical firm focused on developing targeted therapies for uveal melanoma. This filing details positive clinical data from two ongoing trials: OptimUM-01 (metastatic setting) and OptimUM-09 (neoadjuvant setting).
Key Financial Metrics
This Form 8-K is a current report regarding clinical trial results and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document notes that Pfizer provided crizotinib at no cost or a lump-sum cost under a collaboration agreement, but no specific financial figures regarding this arrangement are disclosed.
Material Changes and Clinical Results
OptimUM-01: Metastatic Uveal Melanoma (mUM)
Context: Phase 1/2 trial of darovasertib + crizotinib in first-line mUM.
Data Cut-off: May 28, 2025 (Median follow-up: 25 months).
Key Findings (44 patients):
- Median Overall Survival (OS): 21.1 months (vs. historical ~12 months).
- Median Progression-Free Survival (PFS): 7.0 months.
- Overall Response Rate (ORR): 34% (14/41 evaluable patients).
- Disease Control Rate: 90% (37/41).
- Safety: Manageable tolerability; Grade ≥3 TRAEs were iron-deficiency anemia and pulmonary embolism (both 5%).
OptimUM-09: Neoadjuvant Primary Uveal Melanoma
Context: Phase 2 trial of neoadjuvant darovasertib in primary UM.
Data Cut-off: June 13, 2025 (94 evaluable patients).
Key Findings:
- Tumor Shrinkage: 83% (78/94) demonstrated ocular tumor shrinkage; 54% achieved ≥20% shrinkage.
- Eye Preservation: 57.1% (24/42) of Cohort 1 patients (recommended for enucleation) preserved their eyes. Among those with ≥20% shrinkage, preservation rate was 95%.
- Visual Acuity: 54.7% of Cohort 1 and 60.5% of Cohort 2 showed improvement in visual acuity scores.
- Radiation Reduction: ~70% of Cohort 2 patients observed reduced predicted radiation dose to critical eye structures.
- Safety: Grade 3+ TRAEs occurred in 16.8% of patients; discontinuation due to adverse events was 6.3%.
Guidance, Outlook, and Risks
Outlook and Next Steps
- OptimUM-02 (Phase 2/3): Targeting to report median PFS data by year-end 2025 to Q1 2026 to support a potential U.S. accelerated approval filing for first-line HLA*A2:01-negative mUM.
- OptimUM-10 (Phase 3): Ongoing registrational trial of darovasertib as a single agent in the neoadjuvant setting. The Company has proposed ≥20% tumor shrinkage as the definition of response based on OptimUM-09 data.
- Regulatory Status: Darovasertib holds Breakthrough Therapy Designation for the neoadjuvant setting in primary UM.
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Risks include uncertainties in drug development, regulatory approval processes, manufacturing challenges, and the sufficiency of existing cash to fund operations. The Company notes that Breakthrough Therapy or accelerated approval designations do not guarantee final approval.
Investor Verification Checklist
- Clinical Data Presentation: Verify the full data presentation at the 2025 Society for Melanoma Research Congress (SMR) and European Society of Medical Oncology (ESMO) via the Company's Investor Relations website.
- Regulatory Timeline: Monitor the Company's ability to report OptimUM-02 PFS data by Q1 2026 as scheduled.
- Financial Position: Review the most recent Form 10-K or 10-Q for cash runway, as this 8-K does not disclose liquidity or burn rate.
- Response Criteria: Confirm FDA acceptance of the proposed ≥20% tumor shrinkage definition for the Phase 3 OptimUM-10 trial.
- Safety Profile: Track long-term safety data, particularly regarding Grade ≥3 adverse events in the expanding patient cohorts.